[
  {
    "ts": null,
    "headline": "Pfizer Oncology And Rare Disease Milestones Shape Long Term Growth Prospects",
    "summary": "Pfizer (NYSE:PFE) reported that its BRAFTOVI combination therapy produced significant progression free survival benefits in previously untreated metastatic colorectal cancer patients with the BRAF V600E mutation in a Phase 3 trial. The US FDA granted Priority Review for a HYMPAVZI filing that seeks to expand its use to hemophilia A or B patients, including pediatric populations. For you as an investor, these updates sit at the heart of what Pfizer is trying to build beyond its established...",
    "url": "https://finnhub.io/api/news?id=6d45a2b85dff25355b0e301e076a29ecf9d085cd02becb6e68bf8f8cb9fb08b5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771535409,
      "headline": "Pfizer Oncology And Rare Disease Milestones Shape Long Term Growth Prospects",
      "id": 139152161,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer (NYSE:PFE) reported that its BRAFTOVI combination therapy produced significant progression free survival benefits in previously untreated metastatic colorectal cancer patients with the BRAF V600E mutation in a Phase 3 trial. The US FDA granted Priority Review for a HYMPAVZI filing that seeks to expand its use to hemophilia A or B patients, including pediatric populations. For you as an investor, these updates sit at the heart of what Pfizer is trying to build beyond its established...",
      "url": "https://finnhub.io/api/news?id=6d45a2b85dff25355b0e301e076a29ecf9d085cd02becb6e68bf8f8cb9fb08b5"
    }
  },
  {
    "ts": null,
    "headline": "Q4 Healthcare Dividends: Johnson & Johnson Kept Outshining Pfizer (Rating Upgrades)",
    "summary": "Q4 Healthcare Dividends: Johnson & Johnson Kept Outshining Pfizer (Rating Upgrades)",
    "url": "https://finnhub.io/api/news?id=3d412d999b3ead5a46259c91bc2deb00915875556729d48e83daea77550fc3d9",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771522226,
      "headline": "Q4 Healthcare Dividends: Johnson & Johnson Kept Outshining Pfizer (Rating Upgrades)",
      "id": 139152426,
      "image": "",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=3d412d999b3ead5a46259c91bc2deb00915875556729d48e83daea77550fc3d9"
    }
  },
  {
    "ts": null,
    "headline": "What a Supreme Court tariff ruling may mean for your money",
    "summary": "The Supreme Court is poised to rule on a broad swath of President Donald Trump's tariff agenda. The decision carries big implications for household finances.",
    "url": "https://finnhub.io/api/news?id=005644ac949b3957c9f47e2b01de5645ffcf6a74ea03def1e623e37df71324ce",
    "source": "CNBC",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771518504,
      "headline": "What a Supreme Court tariff ruling may mean for your money",
      "id": 139161945,
      "image": "https://image.cnbcfm.com/api/v1/image/108257956-1769555459222-gettyimages-2257975411-US_GOV_FUNDING.jpeg?v=1771542064&w=1920&h=1080",
      "related": "PFE",
      "source": "CNBC",
      "summary": "The Supreme Court is poised to rule on a broad swath of President Donald Trump's tariff agenda. The decision carries big implications for household finances.",
      "url": "https://finnhub.io/api/news?id=005644ac949b3957c9f47e2b01de5645ffcf6a74ea03def1e623e37df71324ce"
    }
  },
  {
    "ts": null,
    "headline": "Bristol-Myers: I'm Buying Post Earnings",
    "summary": "Bristol-Myers: I'm Buying Post Earnings",
    "url": "https://finnhub.io/api/news?id=cdb38d6e053024dce2899de1c2886c57b17b603f9010e585e65eda1ea4d54fd1",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771517342,
      "headline": "Bristol-Myers: I'm Buying Post Earnings",
      "id": 139151899,
      "image": "",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=cdb38d6e053024dce2899de1c2886c57b17b603f9010e585e65eda1ea4d54fd1"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Targets Long-Term Oncology Growth Amid Competitive Pressure",
    "summary": "PFE's oncology sales rose 8% in 2025 as Padcev, Lorbrena and new launches offset Ibrance declines.",
    "url": "https://finnhub.io/api/news?id=9653a7ee14db41a617001a00b9963f36ca8eb7ff89e98130873c68d34698864f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771514100,
      "headline": "Pfizer Targets Long-Term Oncology Growth Amid Competitive Pressure",
      "id": 139150406,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "PFE's oncology sales rose 8% in 2025 as Padcev, Lorbrena and new launches offset Ibrance declines.",
      "url": "https://finnhub.io/api/news?id=9653a7ee14db41a617001a00b9963f36ca8eb7ff89e98130873c68d34698864f"
    }
  },
  {
    "ts": null,
    "headline": "Where is Pfizer Inc. (PFE) Headed?",
    "summary": "Pfizer Inc. (NYSE:PFE) is one of the best immunotherapy stocks to buy according to hedge funds. On February 12, Daiwa downgraded Pfizer Inc. (NYSE:PFE) to Neutral from Outperform and set a $27 price target. In another development, Pfizer Inc. (NYSE:PFE) announced on February 6 that the U.S. Food and Drug Administration accepted and granted Priority […]",
    "url": "https://finnhub.io/api/news?id=1e30c5a407953af0d7626adc5755ac790baa6e73eae1089df5dae6f334822385",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771512784,
      "headline": "Where is Pfizer Inc. (PFE) Headed?",
      "id": 139149116,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer Inc. (NYSE:PFE) is one of the best immunotherapy stocks to buy according to hedge funds. On February 12, Daiwa downgraded Pfizer Inc. (NYSE:PFE) to Neutral from Outperform and set a $27 price target. In another development, Pfizer Inc. (NYSE:PFE) announced on February 6 that the U.S. Food and Drug Administration accepted and granted Priority […]",
      "url": "https://finnhub.io/api/news?id=1e30c5a407953af0d7626adc5755ac790baa6e73eae1089df5dae6f334822385"
    }
  },
  {
    "ts": null,
    "headline": "Top High-Yield Stocks to Double Up on Right Now",
    "summary": "If you are looking for high-yield stocks, these two turnaround stories offer yield and green shoots, suggesting better times are ahead.",
    "url": "https://finnhub.io/api/news?id=30725d468df9ac6254df2abde351c703d86e32bad5038539531833e917d841b0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771511640,
      "headline": "Top High-Yield Stocks to Double Up on Right Now",
      "id": 139149117,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "If you are looking for high-yield stocks, these two turnaround stories offer yield and green shoots, suggesting better times are ahead.",
      "url": "https://finnhub.io/api/news?id=30725d468df9ac6254df2abde351c703d86e32bad5038539531833e917d841b0"
    }
  },
  {
    "ts": null,
    "headline": "Walmart earnings, Fed meeting minutes, Zuckerberg's testimony and more in Morning Squawk",
    "summary": "Here are five key things investors need to know to start the trading day.",
    "url": "https://finnhub.io/api/news?id=d5cbb412f1268e8edfc3dfb9378edc94627545845f737fbb331cd6f794c158d5",
    "source": "CNBC",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771489201,
      "headline": "Walmart earnings, Fed meeting minutes, Zuckerberg's testimony and more in Morning Squawk",
      "id": 139149688,
      "image": "https://image.cnbcfm.com/api/v1/image/108266955-1771442352852-108266955-1771442166552-gettyimages-2261796700-021826_connelly_zuckerbergcourt009.jpeg?v=1771465909&w=1920&h=1080",
      "related": "PFE",
      "source": "CNBC",
      "summary": "Here are five key things investors need to know to start the trading day.",
      "url": "https://finnhub.io/api/news?id=d5cbb412f1268e8edfc3dfb9378edc94627545845f737fbb331cd6f794c158d5"
    }
  },
  {
    "ts": null,
    "headline": "2 Large-Cap Stocks on Our Watchlist and 1 We Brush Off",
    "summary": "Large-cap stocks usually command their industries because they have the scale to drive market trends. The flip side though is that their sheer size can limit growth as expanding further becomes an increasingly challenging task.",
    "url": "https://finnhub.io/api/news?id=9abf27bfb48d860317c65c919ce0ef0502f567213fa107ad93b701e54b1b0d0c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771476170,
      "headline": "2 Large-Cap Stocks on Our Watchlist and 1 We Brush Off",
      "id": 139150509,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Large-cap stocks usually command their industries because they have the scale to drive market trends. The flip side though is that their sheer size can limit growth as expanding further becomes an increasingly challenging task.",
      "url": "https://finnhub.io/api/news?id=9abf27bfb48d860317c65c919ce0ef0502f567213fa107ad93b701e54b1b0d0c"
    }
  }
]